Myeloma (C90)

The following material has been sourced from the Australian Institute of Health and Welfare

Table B22(a): Incidence and mortality of myeloma
  Incidence - Males Incidence - Females Incidence - Persons Mortality - Males Mortality - Females Mortality - Persons
2011 incidence/2012 mortality(a)
Number 886 647 1,533 470 364 834
Crude rate 8.0 5.8 6.9 4.2 3.2 3.7
ASR 7.7 4.9 6.2 4.1 2.5 3.2
Risk to age 75 1 in 191 1 in 268 1 in 223 1 in 469 1 in 742 1 in 576
Risk to age 85 1 in 96 1 in 149 1 in 118 1 in 162 1 in 275 1 in 209
Mean age 70.1 71.3 70.6 74.3 77.5 75.7
Estimated number for 2014, 2015 and 2016(b)  
2014 975 700 1,680 535 405 940
2015 1,010 715 1,730 550 415 965
2016 1,050 735 1,780 570 425 995

Figure B22(a): Incidence and mortality ASRs(a,b) of myeloma, 1982-2016

Line chart showing rate (per 100,000 people) of incidence and mortality of myeloma in males and females from 1982 to 2012, with estimates to 2016.

Figure B22(b): Incidence (2011) and mortality (2012) rates of myeloma, by age group

Line chart showing rate (per 100,000 people) of incidence (2011) and mortality (2012) of myeloma syndromes in males and females by age group. Age groups shown are: 0-4, 10-14, 20-24, 30-34, 40-44, 50-54, 60-64, 70-74 and 80-84.
  1. The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT (see Appendix F, Cancer in Australia: an overview 2014). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population.
  2. The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 2002–2012 mortality data (see Appendix G, Cancer in Australia: an overview 2014). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. The estimates for males and females may not add to estimates for persons due to rounding.

Sources: AIHW ACD 2011; AIHW NMD.

Table B22(b): Survival and prevalence of myeloma
  Males Females Persons
Prevalence as at the end of 2009(a)
1-year prevalence 721 557 1,278
5-year prevalence 2,346 1,739 4,085
Relative survival in 2007-2011(b)  
1-year relative survival at diagnosis (%) 80.5 78.5 79.6
95% confidence interval 79.0-81.9 76.7-80.1 78.5-80.7
5-year relative survival at diagnosis (%) 45.4 43.9 44.8
95% confidence interval 43.5-47.3 41.8-46.0 43.4-46.2
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 48.9 48.5 48.8
95% confidence interval 45.1-52.7 44.3-52.7 46.0-51.6
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 55.7 57.2 56.4
95% confidence interval 50.5-61.0 51.6-62.8 52.6-60.2

Figure B22(c): Relative survival at diagnosis and 5-year conditional survival from myeloma, Australia, 2007–2011

Line chart showing rate of relative survival of myeloma from 2007 to 2011 by years after diagnosis. Survival rates are grouped by relative survival at diagnosis and 5-year conditional relative survival. Survival rates drop steadily over 20 years for relative survival at diagnosis; while 5-year conditional relative survival rates slowly increase over a period of 15 years.
  1. Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases.
  2. Relative survival was calculated with the period method, using the period 2007-2011 (Brenner & Gefeller 1996). Note that this period does not contain incidence data for 2010-2011 for NSW or the ACT (see Appendix F, Cancer in Australia: an overview 2014).

Source: AIHW ACD 2011.